182 related articles for article (PubMed ID: 34448313)
1. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
Gane E; de Ledinghen V; Dylla DE; Rizzardini G; Shiffman ML; Barclay ST; Calleja JL; Xue Z; Burroughs M; Gutierrez JA
J Viral Hepat; 2021 Nov; 28(11):1635-1642. PubMed ID: 34448313
[TBL] [Abstract][Full Text] [Related]
2. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
Brown RS; Buti M; Rodrigues L; Chulanov V; Chuang WL; Aguilar H; Horváth G; Zuckerman E; Carrion BR; Rodriguez-Perez F; Urbánek P; Abergel A; Cohen E; Lovell SS; Schnell G; Lin CW; Zha J; Wang S; Trinh R; Mensa FJ; Burroughs M; Felizarta F
J Hepatol; 2020 Mar; 72(3):441-449. PubMed ID: 31682879
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.
Fontana RJ; Lens S; McPherson S; Elkhashab M; Ankoma-Sey V; Bondin M; Dos Santos AGP; Xue Z; Trinh R; Porcalla A; Zeuzem S
Adv Ther; 2019 Dec; 36(12):3458-3470. PubMed ID: 31646465
[TBL] [Abstract][Full Text] [Related]
4. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E;
J Hepatol; 2020 Mar; 72(3):431-440. PubMed ID: 31655134
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
Chayama K; Suzuki F; Karino Y; Kawakami Y; Sato K; Atarashi T; Naganuma A; Watanabe T; Eguchi Y; Yoshiji H; Seike M; Takei Y; Kato K; Alves K; Burroughs M; Redman R; Pugatch DL; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Kumada H
J Gastroenterol; 2018 Apr; 53(4):557-565. PubMed ID: 28948366
[TBL] [Abstract][Full Text] [Related]
6. Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study.
Poordad F; Felizarta F; Yao BB; Overcash JS; Hassanein T; Agarwal K; Gane E; Shaw D; Waters M; Krishnan P; Topp A; Burroughs M; Nevens F
Liver Int; 2022 Jun; 42(6):1278-1286. PubMed ID: 35220658
[TBL] [Abstract][Full Text] [Related]
7. Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.
Cornberg M; Ahumada A; Aghemo A; Andreoni M; Bhagat A; Butrymowicz I; Carmiel M; Chodick G; Conway B; Song Y; Gasbarrini A; Hüppe D; Plaza FJ; Lampertico P; Alonso MLM; Myles L; Persico M; Ramji A; Sarrazin C; Villa E; Weil C; Otano JIU;
Adv Ther; 2022 Jul; 39(7):3146-3158. PubMed ID: 35543964
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
Heo J; Kim YJ; Lee JW; Kim JH; Lim YS; Han KH; Jeong SH; Cho M; Yoon KT; Bae SH; Crown ED; Fredrick LM; Alami NN; Asatryan A; Kim DH; Paik SW; Lee YJ
Gut Liver; 2021 Nov; 15(6):895-903. PubMed ID: 34053916
[TBL] [Abstract][Full Text] [Related]
9. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
Poordad F; Pol S; Asatryan A; Buti M; Shaw D; Hézode C; Felizarta F; Reindollar RW; Gordon SC; Pianko S; Fried MW; Bernstein DE; Gallant J; Lin CW; Lei Y; Ng TI; Krishnan P; Kopecky-Bromberg S; Kort J; Mensa FJ
Hepatology; 2018 Apr; 67(4):1253-1260. PubMed ID: 29152781
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
Kumada H; Watanabe T; Suzuki F; Ikeda K; Sato K; Toyoda H; Atsukawa M; Ido A; Takaki A; Enomoto N; Kato K; Alves K; Burroughs M; Redman R; Pugatch D; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Chayama K
J Gastroenterol; 2018 Apr; 53(4):566-575. PubMed ID: 29052790
[TBL] [Abstract][Full Text] [Related]
11. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
Zuckerman E; Gutierrez JA; Dylla DE; de Ledinghen V; Muir AJ; Gschwantler M; Puoti M; Caruntu F; Slim J; Nevens F; Sigal S; Cohen S; Fredrick LM; Pires Dos Santos AG; Rodrigues L; Dillon JF
Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2544-2553.e6. PubMed ID: 32621971
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.
Back D; Belperio P; Bondin M; Negro F; Talal AH; Park C; Zhang Z; Pinsky B; Crown E; Mensa FJ; Marra F
J Viral Hepat; 2019 Aug; 26(8):951-960. PubMed ID: 30977945
[TBL] [Abstract][Full Text] [Related]
13. High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
Zamor PJ; Brown A; Dylla DE; Dillon JF; Luetkemeyer AF; Feld JJ; Mutimer D; Ghalib R; Crown E; Lovell SS; Hu Y; Moreno C; Nelson DR; Colombo M; Papatheodoridis G; Rockstroh JK; Skoien R; Lawitz E; Jacobson IM
Am J Gastroenterol; 2021 Sep; 116(9):1896-1904. PubMed ID: 34465693
[TBL] [Abstract][Full Text] [Related]
14. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials.
Krishnan P; Pilot-Matias T; Schnell G; Tripathi R; Ng TI; Reisch T; Beyer J; Dekhtyar T; Irvin M; Xie W; Larsen L; Mensa FJ; Collins C
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061289
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies.
Yao BB; Fredrick LM; Schnell G; Kowdley KV; Kwo PY; Poordad F; Nguyen K; Lee SS; George C; Wong F; Gane E; Abergel A; Spearman CW; Nguyen T; Hung Le M; Pham TT; Mensa F; Asselah T
Liver Int; 2020 Oct; 40(10):2385-2393. PubMed ID: 32445613
[TBL] [Abstract][Full Text] [Related]
16. Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution.
Park YJ; Woo HY; Heo J; Park SG; Hong YM; Yoon KT; Kim DU; Kim GH; Kim HH; Song GA; Cho M
Gut Liver; 2021 May; 15(3):440-450. PubMed ID: 32839365
[TBL] [Abstract][Full Text] [Related]
17. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Dekhtyar T; Irvin M; Xie W; Fu B; Burroughs M; Redman R; Kumada H; Chayama K; Collins C; Pilot-Matias T
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180522
[TBL] [Abstract][Full Text] [Related]
18. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
Wei L; Wang G; Alami NN; Xie W; Heo J; Xie Q; Zhang M; Kim YJ; Lim SG; Fredrick LM; Lu W; Liu W; Kalluri HV; Krishnan P; Tripathi R; Mobashery N; Burroughs M; Asatryan A; Jia J; Hou J
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):839-849. PubMed ID: 32682494
[TBL] [Abstract][Full Text] [Related]
19. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Reau N; Kwo PY; Rhee S; Brown RS; Agarwal K; Angus P; Gane E; Kao JH; Mantry PS; Mutimer D; Reddy KR; Tran TT; Hu YB; Gulati A; Krishnan P; Dumas EO; Porcalla A; Shulman NS; Liu W; Samanta S; Trinh R; Forns X
Hepatology; 2018 Oct; 68(4):1298-1307. PubMed ID: 29672891
[TBL] [Abstract][Full Text] [Related]
20. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Poordad F; Felizarta F; Asatryan A; Sulkowski MS; Reindollar RW; Landis CS; Gordon SC; Flamm SL; Fried MW; Bernstein DE; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
Hepatology; 2017 Aug; 66(2):389-397. PubMed ID: 28128852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
